FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:1195-1202 October 23, 1997 Number 17 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background and Methods Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo-controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven weeks. The target quitting date (or "target quit date") was one week after the beginning of treatment. Brief counseling was provided at base line, weekly during treatment, and at 8, 12, 26, and 52 weeks. Self-reported abstinence was confirmed by a carbon monoxide concentration in expired air of 10 ppm or less.

Results At the end of seven weeks of treatment, the rates of smoking cessation as confirmed by carbon monoxide measurements were 19.0 percent in the placebo group, 28.8 percent in the 100-mg group, 38.6 percent in the 150-mg group, and 44.2 percent in the 300-mg group (P<0.001). At one year the respective rates were 12.4 percent, 19.6 percent, 22.9 percent, and 23.1 percent. The rates for the 150-mg group (P = 0.02) and the 300-mg group (P = 0.01) — but not the 100-mg group (P = 0.09) — were significantly better than those for the placebo group. Among the subjects who were continuously abstinent through the end of treatment, the mean absolute weight gain was inversely associated with the dose (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P = 0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression Inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups.

Conclusions A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many participants in all groups were smoking at one year.

Source Information

From the Nicotine Research Center (R.D.H., L.C.D., I.T.C.), the Section of Biostatistics (K.P.O., D.R.S.), and the Division of Community Internal Medicine (R.D.H., L.C.D.), Mayo Clinic and Mayo Foundation, Rochester, Minn.; the Palo Alto Center for Pulmonary Disease Prevention, Palo Alto, Calif. (D.P.L.S.); Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown (E.D.G., P.N.G., C.R.S., P.M.S.); and Glaxo Wellcome, Inc., Research Triangle Park, N.C. (J.A.J., M.A.K.).

Address reprint requests to Dr. Hurt at the Mayo Clinic, 200 First St. SW, Rochester, MN 55905.

Full Text of this Article

Related Letters:

Sustained-Release Bupropion for Smoking Cessation
McAfee T., France E., Pasternak M., Hurt R. D., Sachs D. P.L., Glover E. D.
Extract | Full Text  
N Engl J Med 1998; 338:619-620, Feb 26, 1998. Correspondence

This article has been cited by other articles:

• Oncken, C. A., Kranzler, H. R. (2009). What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?. Nicotine Tob Res 11: 1265-1273 [Abstract] [Full Text]  
• Strong, D. R., Kahler, C. W., Leventhal, A. M., Abrantes, A. M., Lloyd-Richardson, E., Niaura, R., Brown, R. A. (2009). Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. Nicotine Tob Res 11: 1142-1153 [Abstract] [Full Text]  
• Grassi, M. C., Enea, D., Ferketich, A. K., Lu, B., Nencini, P. (2009). A smoking ban in public places increases the efficacy of bupropion and counseling on cessation outcomes at 1 year. Nicotine Tob Res 11: 1114-1121 [Abstract] [Full Text]  
• Hurt, R. D., Ebbert, J. O., Hays, J. T., McFadden, D. D. (2009). Treating Tobacco Dependence in a Medical Setting. CA Cancer J Clin 59: 314-326 [Abstract] [Full Text]  
• Frishman, W. H. (2009). Smoking cessation pharmacotherapy. Ther Adv Cardiovasc Dis 3: 287-308 [Abstract]  
• Ebbert, J. O., Croghan, I. T., Sood, A., Schroeder, D. R., Hays, J. T., Hurt, R. D. (2009). Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 11: 234-239 [Abstract] [Full Text]  
• Conti, D. V., Lee, W., Li, D., Liu, J., Van Den Berg, D., Thomas, P. D., Bergen, A. W., Swan, G. E., Tyndale, R. F., Benowitz, N. L., Lerman, C., for the Pharmacogenetics of Nicotine Addiction and, (2008). Nicotinic acetylcholine receptor {beta}2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 17: 2834-2848 [Abstract] [Full Text]  
• De Biasi, M., Salas, R. (2008). Influence of Neuronal Nicotinic Receptors over Nicotine Addiction and Withdrawal. Exp. Biol. Med. 233: 917-929 [Abstract] [Full Text]  
• Eisenberg, M. J. MD MPH, Filion, K. B. MSc, Yavin, D. BSc, Belisle, P. MSc, Mottillo, S. BSc, Joseph, L. PhD, Gervais, A. MD, O'Loughlin, J. PhD, Paradis, G. MD MSc, Rinfret, S. MD MSc, Pilote, L. MD PhD (2008). Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 179: 135-144 [Abstract] [Full Text]  
• Breitling, L P, Twardella, D, Brenner, H (2008). High effectiveness of short treatment with bupropion for smoking cessation in general care. Thorax 63: 476-477 [Full Text]  
• Rovina, N., Nikoloutsou, I., Dima, E., Michailidou, M., Roussos, C., Gratziou, C. (2007). Smoking cessation treatment in a real-life setting: the Greek experience. Ther Adv Respir Dis 1: 93-104 [Abstract]  
• Muramoto, M. L., Leischow, S. J., Sherrill, D., Matthews, E., Strayer, L. J. (2007). Randomized, Double-blind, Placebo-Controlled Trial of 2 Dosages of Sustained-Release Bupropion for Adolescent Smoking Cessation. Arch Pediatr Adolesc Med 161: 1068-1074 [Abstract] [Full Text]  
• Tyc, V. L. (2007). Strategies for Tobacco Control Among Youngsters with Cancer. J Pediatr Psychol 32: 1067-1078 [Abstract] [Full Text]  
• Fossati, R., Apolone, G., Negri, E., Compagnoni, A., La Vecchia, C., Mangano, S., Clivio, L., Garattini, S., for the General Practice Tobacco Cessation Investi, (2007). A Double-blind, Placebo-Controlled, Randomized Trial of Bupropion for Smoking Cessation in Primary Care. Arch Intern Med 167: 1791-1797 [Abstract] [Full Text]  
• Gray, J., Mao, J. T., Szabo, E., Kelley, M., Kurie, J., Bepler, G. (2007). Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 132: 56S-68S [Abstract] [Full Text]  
• Sullivan, K. M ., Seed, S. M., DeBellis, R. J. (2007). State of the Art Reviews: Smoking Cessation: A Review of Treatment Considerations. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 1: 201-213 [Abstract]  
• Leeman, R. F., Huffman, C. J., O'Malley, S. S. (2007). Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review. Alcohol Alcohol 42: 196-206 [Abstract] [Full Text]  
• (2007). References. APPI Online CME 2007: 2-2 [Full Text]  
• Croghan, I. T., Hurt, R. D., Dakhil, S. R., Croghan, G. A., Sloan, J. A., Novotny, P. J., Rowland, K. M., Bernath, A., Loots, M. L., Le-Lindqwister, N. A., Tschetter, L. K., Garneau, S. C., Flynn, K. A., Ebbert, L. P., Wender, D. B., Loprinzi, C. L. (2007). Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention. Mayo Clin Proc. 82: 186-195 [Abstract] [Full Text]  
• Kosten, T. R., Kosten, T. A. (2007). New Medication Strategies for Comorbid Substance Use and Bipolar Affective Disorders. Focus 5: 262-269 [Abstract] [Full Text]  
• Duffy, S. A., Ronis, D. L., Valenstein, M., Lambert, M. T., Fowler, K. E., Gregory, L., Bishop, C., Myers, L. L., Blow, F. C., Terrell, J. E. (2006). A Tailored Smoking, Alcohol, and Depression Intervention for Head and Neck Cancer Patients.. Cancer Epidemiol. Biomarkers Prev. 15: 2203-2208 [Abstract] [Full Text]  
• Sheikh, K. (2006). RE: "CIGARETTE SMOKING AND INCIDENCE OF FIRST DEPRESSIVE EPISODE: AN 11-YEAR, POPULATION-BASED FOLLOW-UP STUDY". Am J Epidemiol 164: 918-919 [Full Text]  
• Mohide, E A. (2006). Review: existing evidence does not support behavioural or other specific interventions to prevent smoking relapse. Evid. Based Nurs. 9: 109-109 [Full Text]  
• Oren, S., Isakov, I., Golzman, B., Kogan, J., Turkot, S., Peled, R., Yosefy, C. (2006). The Influence of Smoking Cessation on Hemodynamics and Arterial Compliance. ANGIOLOGY 57: 564-568 [Abstract]  
• Bednarek, M, Gorecka, D, Wielgomas, J, Czajkowska-Malinowska, M, Regula, J, Mieszko-Filipczyk, G, Jasionowicz, M, Bijata-Bronisz, R, Lempicka-Jastrzebska, M, Czajkowski, M, Przybylski, G, Zielinski, J (2006). Smokers with airway obstruction are more likely to quit smoking. Thorax 61: 869-873 [Abstract] [Full Text]  
• Johnson, B. A. (2006). New Weapon to Curb Smoking: No More Excuses to Delay Treatment.. Arch Intern Med 166: 1547-1550 [Full Text]  
• Nides, M., Oncken, C., Gonzales, D., Rennard, S., Watsky, E. J., Anziano, R., Reeves, K. R., for the Varenicline Study Group, (2006). Smoking Cessation With Varenicline, a Selective {alpha}4beta2 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up.. Arch Intern Med 166: 1561-1568 [Abstract] [Full Text]  
• Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E., Billing, C. B., Gong, J., Reeves, K. R., for the Varenicline Phase 3 Study Group, (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.. JAMA 296: 56-63 [Abstract] [Full Text]  
• Lee, A. M., Tyndale, R. F. (2006). Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. J Psychopharmacol 20: 7-14 [Abstract]  
• Whooley, M. A. (2006). Depression and cardiovascular disease: healing the broken-hearted.. JAMA 295: 2874-2881 [Abstract] [Full Text]  
• Marso, S. P., Hiatt, W. R. (2006). Peripheral Arterial Disease in Patients With Diabetes. J Am Coll Cardiol 47: 921-929 [Abstract] [Full Text]  
• Paluck, E. C, McCormack, J. P, Ensom, M. H., Levine, M., Soon, J. A, Fielding, D. W (2006). Outcomes of Bupropion Therapy for Smoking Cessation During Routine Clinical Use. The Annals of Pharmacotherapy 40: 185-190 [Abstract] [Full Text]  
• Frieden, T. R., Blakeman, D. E. (2005). The Dirty Dozen: 12 Myths That Undermine Tobacco Control. AJPH 95: 1500-1505 [Abstract] [Full Text]  
• Berrettini, W. H., Lerman, C. E. (2005). Pharmacotherapy and Pharmacogenetics of Nicotine Dependence. Am. J. Psychiatry 162: 1441-1451 [Abstract] [Full Text]  
• Bumpus, N. N., Sridar, C., Kent, U. M., Hollenberg, P. F. (2005). THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION. Drug Metab. Dispos. 33: 795-802 [Abstract] [Full Text]  
• DiMartini, A. F., Dew, M. A., Trzepacz, P. T. (2005). Organ Transplantation. Focus 3: 280-303 [Full Text]  
• McGrath, A, Crome, P, Crome, I B (2005). Substance misuse in the older population. Postgrad. Med. J. 81: 228-231 [Abstract] [Full Text]  
• Holt, S, Timu-Parata, C, Ryder-Lewis, S, Weatherall, M, Beasley, R (2005). Efficacy of bupropion in the indigenous Maori population in New Zealand. Thorax 60: 120-123 [Abstract] [Full Text]  
• Lerman, C., Patterson, F., Berrettini, W. (2005). Treating Tobacco Dependence: State of the Science and New Directions. JCO 23: 311-323 [Abstract] [Full Text]  
• Mazzone, P. J., Arroliga, A. C. (2004). How Many Ways Can We Say That Cigarette Smoking Is Bad for You?. Chest 126: 1717-1718 [Full Text]  
• Prochazka, A. V., Kick, S., Steinbrunn, C., Miyoshi, T., Fryer, G. E. (2004). A Randomized Trial of Nortriptyline Combined With Transdermal Nicotine for Smoking Cessation. Arch Intern Med 164: 2229-2233 [Abstract] [Full Text]  
• Hall, S. M., Humfleet, G. L., Reus, V. I., Munoz, R. F., Cullen, J. (2004). Extended Nortriptyline and Psychological Treatment for Cigarette Smoking. Am. J. Psychiatry 161: 2100-2107 [Abstract] [Full Text]  
• Myles, M. E., Azcuy, A. M., Nguyen, N. T., Reisch, E. R., Barker, S. A., Thompson, H. W., Hill, J. M. (2004). Bupropion (Zyban, Wellbutrin) Inhibits Nicotine-Induced Viral Reactivation in Herpes Simplex Virus Type 1 Latent Rabbits. J. Pharmacol. Exp. Ther. 311: 640-644 [Abstract] [Full Text]  
• Simon, J. A., Duncan, C., Carmody, T. P., Hudes, E. S. (2004). Bupropion for Smoking Cessation: A Randomized Trial. Arch Intern Med 164: 1797-1803 [Abstract] [Full Text]  
• Zuckerman, B., Parker, S., Kaplan-Sanoff, M., Augustyn, M., Barth, M. C. (2004). Healthy Steps: A Case Study of Innovation in Pediatric Practice. Pediatrics 114: 820-826 [Abstract] [Full Text]  
• Humphrey, L. L., Teutsch, S., Johnson, M. (2004). Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography: An Update for the U.S. Preventive Services Task Force. ANN INTERN MED 140: 740-753 [Abstract] [Full Text]  
• Schnoll, R. A., Engstrom, P. F. (2004). Tobacco Control in the Physician's Office: A Matter of Adequate Training and Resources. JNCI J Natl Cancer Inst 96: 573-575 [Full Text]  
• Haas, J S, Kaplan, C P, Barenboim, D, Jacob, P 3rd, Benowitz, N L (2004). Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use. Tobacco Control 13: 52-56 [Abstract] [Full Text]  
• Roddy, E. (2004). Bupropion and other non-nicotine pharmacotherapies. BMJ 328: 509-511 [Full Text]  
• Hilleman, D. E., Mohiuddin, S. M., Packard, K. A. (2004). Comparison of Conservative and Aggressive Smoking Cessation Treatment Strategies Following Coronary Artery Bypass Graft Surgery. Chest 125: 435-438 [Abstract] [Full Text]  
• Middleton, L. S., Cass, W. A., Dwoskin, L. P. (2004). Nicotinic Receptor Modulation of Dopamine Transporter Function in Rat Striatum and Medial Prefrontal Cortex. J. Pharmacol. Exp. Ther. 308: 367-377 [Abstract] [Full Text]  
• Jepsen, F, Matthews, J, Andrews, F J (2003). Sustained release bupropion overdose: an important cause of prolonged symptoms after an overdose. Emerg. Med. J. 20: 560-561 [Abstract] [Full Text]  
• Swan, G. E., McAfee, T., Curry, S. J., Jack, L. M., Javitz, H., Dacey, S., Bergman, K. (2003). Effectiveness of Bupropion Sustained Release for Smoking Cessation in a Health Care Setting: A Randomized Trial. Arch Intern Med 163: 2337-2344 [Abstract] [Full Text]  
• Katz, D. L., Boukhalil, J., Lucan, S. C., Shah, D., Chan, W., Yeh, M.-C. (2003). Impediment Profiling for Smoking Cessation: Preliminary Experience. Behav Modif 27: 524-537 [Abstract]  
• Burdette, H. L., Whitaker, R. C., Kahn, R. S., Harvey-Berino, J. (2003). Association of Maternal Obesity and Depressive Symptoms With Television-Viewing Time in Low-Income Preschool Children. Arch Pediatr Adolesc Med 157: 894-899 [Abstract] [Full Text]  
• Hays, J. T., Ebbert, J. O. (2003). Bupropion Sustained Release for Treatment of Tobacco Dependence. Mayo Clin Proc. 78: 1020-1024 [Abstract]  
• Kolber, M., Spooner, G. R., Szafran, O. (2003). Adverse events with Zyban (buproprion). CMAJ 169: 103-104 [Full Text]  
• Gorecka, D., Bednarek, M., Nowinski, A., Puscinska, E., Goljan-Geremek, A., Zielinski, J. (2003). Diagnosis of Airflow Limitation Combined With Smoking Cessation Advice Increases Stop-Smoking Rate. Chest 123: 1916-1923 [Abstract] [Full Text]  
• Wright, A J, Weinman, J, Marteau, T M (2003). The impact of learning of a genetic predisposition to nicotine dependence: an analogue study. Tobacco Control 12: 227-230 [Abstract] [Full Text]  
• Tonstad, S, Farsang, C, Klaene, G, Lewis, K, Manolis, A, Perruchoud, A.P, Silagy, C, van Spiegel, P.I, Astbury, C, Hider, A, Sweet, R (2003). Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 24: 946-955 [Abstract] [Full Text]  
• Worsnop, C. J. (2003). Smoking: Not for Anyone. Chest 123: 1338-1340 [Full Text]  
• Garces, Y. I., Hays, J. T. (2003). Tobacco Dependence: Why Should an Oncologist Care?. JCO 21: 1884-1886 [Full Text]  
• Morgan, M D L, Britton, J R (2003). Chronic obstructive pulmonary disease * 8: Non-pharmacological management of COPD. Thorax 58: 453-457 [Abstract] [Full Text]  
• Hurt, R. D., Krook, J. E., Croghan, I. T., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Kardinal, C. G., Knost, J. A., Tirona, M. T., Addo, F., Morton, R. F., Michalak, J. C., Schaefer, P. L., Porter, P. A., Stella, P. J. (2003). Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking. JCO 21: 914-920 [Abstract] [Full Text]  
• Ai-Leng, K., Lai-San, T., Kang-Hoe, L., Gek-Kee, L. (2003). Acute Liver Failure with Concurrent Bupropion and Carbimazole Therapy. The Annals of Pharmacotherapy 37: 220-223 [Abstract] [Full Text]  
• Brody, A. L., Mandelkern, M. A., London, E. D., Childress, A. R., Lee, G. S., Bota, R. G., Ho, M. L., Saxena, S., Baxter, L. R. Jr, Madsen, D., Jarvik, M. E. (2002). Brain Metabolic Changes During Cigarette Craving. Arch Gen Psychiatry 59: 1162-1172 [Abstract] [Full Text]  
• Rauhut, A. S., Mullins, S. N., Dwoskin, L. P., Bardo, M. T. (2002). Reboxetine: Attenuation of Intravenous Nicotine Self-Administration in Rats. J. Pharmacol. Exp. Ther. 303: 664-672 [Abstract] [Full Text]  
• Kahn, R. S., Certain, L., Whitaker, R. C. (2002). A Reexamination of Smoking Before, During, and After Pregnancy. AJPH 92: 1801-1808 [Abstract] [Full Text]  
• Covey, L. S., Glassman, A. H., Stetner, F., Rivelli, S., Stage, K. (2002). A Randomized Trial of Sertraline as a Cessation Aid for Smokers With a History of Major Depression. Am. J. Psychiatry 159: 1731-1737 [Abstract] [Full Text]  
• Hall, S. M., Humfleet, G. L., Reus, V. I., Munoz, R. F., Hartz, D. T., Maude-Griffin, R. (2002). Psychological Intervention and Antidepressant Treatment in Smoking Cessation. Arch Gen Psychiatry 59: 930-936 [Abstract] [Full Text]  
• Miller, D. K., Sumithran, S. P., Dwoskin, L. P. (2002). Bupropion Inhibits Nicotine-Evoked [3H]Overflow from Rat Striatal Slices Preloaded with [3H]Dopamine and from Rat Hippocampal Slices Preloaded with [3H]Norepinephrine. J. Pharmacol. Exp. Ther. 302: 1113-1122 [Abstract] [Full Text]  
• Miller, D. K., Wong, E. H. F., Chesnut, M. D., Dwoskin, L. P. (2002). Reboxetine: Functional Inhibition of Monoamine Transporters and Nicotinic Acetylcholine Receptors. J. Pharmacol. Exp. Ther. 302: 687-695 [Abstract] [Full Text]  
• DeGraff, A. C. Jr (2002). Pharmacologic Therapy for Nicotine Addiction. Chest 122: 392-394 [Full Text]  
• da Costa, C. L., Younes, R. N., Lourenco, M. T. C. (2002). Stopping Smoking* : A Prospective, Randomized, Double-Blind Study Comparing Nortriptyline to Placebo. Chest 122: 403-408 [Abstract] [Full Text]  
• Ahluwalia, J. S., Harris, K. J., Catley, D., Okuyemi, K. S., Mayo, M. S. (2002). Sustained-Release Bupropion for Smoking Cessation in African Americans: A Randomized Controlled Trial. JAMA 288: 468-474 [Abstract] [Full Text]  
• Benowitz, N. L. (2002). Smoking Cessation Trials Targeted to Racial and Economic Minority Groups. JAMA 288: 497-499 [Full Text]  
• Rigotti, N. A. (2002). Treatment of Tobacco Use and Dependence. NEJM 346: 506-512 [Full Text]  
• Wooltorton, E. (2002). Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness. CMAJ 166: 68-68 [Full Text]  
• Maharaj, K., Maharaj, K., Ternullo, S. (2001). Using Nicotine Replacement Therapy in Treating Nicotine Addiction in Adolescents. The Journal of School Nursing 17: 278-282 [Abstract] [Full Text]  
• Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P.L., Wolter, T. D., Buist, A. S., Johnston, J. A., White, J. D. (2001). Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation: A Randomized, Controlled Trial. ANN INTERN MED 135: 423-433 [Abstract] [Full Text]  
• Khuri, F. R., Kim, E. S., Lee, J. J., Winn, R. J., Benner, S. E., Lippman, S. M., Fu, K. K., Cooper, J. S., Vokes, E. E., Chamberlain, R. M., Williams, B., Pajak, T. F., Goepfert, H., Hong, W. K. (2001). The Impact of Smoking Status, Disease Stage, and Index Tumor Site on Second Primary Tumor Incidence and Tumor Recurrence in the Head and Neck Retinoid Chemoprevention Trial. Cancer Epidemiol. Biomarkers Prev. 10: 823-829 [Abstract] [Full Text]  
• WAGENA, E J, HUIBERS, M J H, VAN SCHAYCK, C P (2001). Antidepressants in the treatment of patients with COPD: possible associations between smoking cigarettes, COPD and depression. Thorax 56: 587a-588 [Full Text]  
• Coleman, T (2001). Smoking cessation: integrating recent advances into clinical practice. Thorax 56: 579-582 [Abstract] [Full Text]  
• Coleman, T., West, R. (2001). Newly available treatments for nicotine addiction. BMJ 322: 1076-1077 [Full Text]  
• Dale, L. C., Glover, E. D., Sachs, D. P. L., Schroeder, D. R., Offord, K. P., Croghan, I. T., Hurt, R. D. (2001). Bupropion for Smoking Cessation : Predictors of Successful Outcome. Chest 119: 1357-1364 [Abstract] [Full Text]  
• Adelman, W. P., Duggan, A. K., MS, P. H., Joffe, A. (2001). Effectiveness of a High School Smoking Cessation Program. Pediatrics 107: e50-e50 [Abstract] [Full Text]  
• Schneider, R. K., Levenson, J. L., Schnoll, S. H. (2001). Update in Addiction Medicine. ANN INTERN MED 134: 387-395 [Full Text]  
• Harrison, C., Kinnell, H. G, Richardson, W., Vautrey, R., Britton, J., Jarvis, M. (2001). Bupropion for smokers. BMJ 322: 431-431 [Full Text]  
• Cataldo, J. K., Talley, S. (2001). Helping Our Clients With Smoking Cessation. J Am Psychiatr Nurses Assoc 7: 26-31  
• Whooley, M. A., Simon, G. E. (2000). Managing Depression in Medical Outpatients. NEJM 343: 1942-1950 [Full Text]  
• West, R., McNeill, A., Raw, M. (2000). Smoking cessation guidelines for health professionals: an update. Thorax 55: 987-999 [Abstract] [Full Text]  
• (2000). {blacktriangledown}Bupropion to aid smoking cessation. DTB 38: 73-75 [Abstract] [Full Text]  
• Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I., Greenblatt, D. J. (2000). CYP2B6 Mediates the In Vitro Hydroxylation of Bupropion: Potential Drug Interactions with Other Antidepressants. Drug Metab. Dispos. 28: 1176-1183 [Abstract] [Full Text]